Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma

Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 von der Maase, 2005, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J Clin Oncol, 23, 4602, 10.1200/JCO.2005.07.757 Apolo, 2014, Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States, Urol Oncol, 32, 637, 10.1016/j.urolonc.2013.12.012 Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. In press. Sternberg, 2006, EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours, Eur J Cancer, 42, 50, 10.1016/j.ejca.2005.08.032 Plimack, 2014, Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity, J Clin Oncol, 32, 1895, 10.1200/JCO.2013.53.2465 Choueiri, 2014, Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates, J Clin Oncol, 32, 1889, 10.1200/JCO.2013.52.4785 Siefker-Radtke A, Kamat A, Corn P, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the University of Texas MD Anderson Cancer Center. ASCO Meeting Abstracts 2012; 30:4523. Griffiths, 2011, International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial, J Clin Oncol, 29, 2171, 10.1200/JCO.2010.32.3139 Lavery, 2014, Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate, J Urol, 191, 898 Sonpavde, 2009, Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, 115, 4104, 10.1002/cncr.24466 Petrelli, 2014, Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis, Eur Urol, 65, 350, 10.1016/j.eururo.2013.06.049 Kassouf, 2007, P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors, Eur Urol, 52, 769, 10.1016/j.eururo.2007.03.086 Rosenblatt, 2012, Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer, Eur Urol, 61, 1229, 10.1016/j.eururo.2011.12.010 Tilki, 2010, Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients, J Urol, 184, 888 Chism, 2013, Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer, Oncologist, 18, 933, 10.1634/theoncologist.2013-0023 Pruthi, 2010, A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results, BJU Int, 106, 349, 10.1111/j.1464-410X.2009.09101.x Hahn N, Daneshmand S, Posadas E, et al. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. ASCO Meeting Abstracts 2012; 30:4586. Knudsen B, Hahn NM, Daneshmand S, et al. Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). ASCO Meeting Abstracts 2014; 32:324. Plimack E, Gupta S, Bellmunt J, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer. Paper presented at: ESMO Annual Meeting; 2014; Madrid, Spain. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meeting Abstracts 2014; 32:5011. Choi, 2014, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25, 152, 10.1016/j.ccr.2014.01.009 Yap, 2014, Whole exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival, Clin Cancer Res, 20, 6605, 10.1158/1078-0432.CCR-14-0257 Ozcan, 2013, Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy, Urol Oncol, 31, 1709, 10.1016/j.urolonc.2012.06.014 Plimack, 2014, ASCO Meeting Abstracts, 32, 4538 Sternberg, 2015, Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial, Lancet Oncol, 16, 76, 10.1016/S1470-2045(14)71160-X Cognetti, 2012, Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial, Ann Oncol, 23, 695, 10.1093/annonc/mdr354 Stadler, 2011, Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status, J Clin Oncol, 29, 3443, 10.1200/JCO.2010.34.4028 Leow, 2014, Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials, Eur Urol, 66, 42, 10.1016/j.eururo.2013.08.033 Galsky M, Stensland K, Moshier E, et al. Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with >= pT3 and/or pN+ bladder cancer (BCa). ASCO Meeting Abstracts 2015, 33:292. Grivas, 2014, Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma, Cancer, 120, 692, 10.1002/cncr.28477 Agarwal, 2014, Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma, Oncologist, 19, 915, 10.1634/theoncologist.2014-0153 Polo SH, Gonzalez del Alba A, Perez-Valderrama B, et al. Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: a phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—interim analysis on safety. ASCO Meeting Abstracts 2014; 32:359. Seidman, 2013, The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?, J Clin Oncol, 31, 1707, 10.1200/JCO.2013.48.6894 Ozols, 2003, Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit, J Clin Oncol, 21, 2451, 10.1200/JCO.2003.03.039 Oliver, 2014, Ovarian cancer and antiangiogenic therapy: caveat emptor, J Clin Oncol, 32, 3353, 10.1200/JCO.2014.57.4574 Markman, 2003, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial, J Clin Oncol, 21, 2460, 10.1200/JCO.2003.07.013 Tournigand, 2006, OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study, J Clin Oncol, 24, 394, 10.1200/JCO.2005.03.0106 Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 365, 2473, 10.1056/NEJMoa1104390 Perren, 2011, A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 365, 2484, 10.1056/NEJMoa1103799 du Bois, 2014, Incorporation of pazopanib in maintenance therapy of ovarian cancer, J Clin Oncol, 32, 3374, 10.1200/JCO.2014.55.7348 Sandler, 2006, Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Reck, 2010, Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non–small-cell lung cancer: results from a randomised phase III trial (AVAiL), Ann Oncol, 21, 1804, 10.1093/annonc/mdq020 Galsky, 2014, Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy, Urol Oncol, 32, 48.e1, 10.1016/j.urolonc.2013.07.001 Siu, 2013, J Clin Oncol, 31, 2477, 10.1200/JCO.2012.46.0543 Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965 Vaughn, 2002, Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer, J Clin Oncol, 20, 937, 10.1200/JCO.2002.20.4.937 Sweeney, 2006, Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium, J Clin Oncol, 24, 3451, 10.1200/JCO.2005.03.6699